Amneal Pharmaceuticals (AMRX) Profit After Tax (2017 - 2026)

Amneal Pharmaceuticals has reported Profit After Tax for 10 years, with the latest figure at $69.6 million in Q2 2026.

• On a quarterly basis, Profit After Tax rose 95.49% year-over-year to $69.6 million in Q2 2026; TTM through Jun 2026 was $215.3 million, a 426.4% increase from a year earlier, with the FY2025 full-year figure at $127.9 million, up 209.45% from the prior year.
• Profit After Tax was $69.6 million for Q2 2026 at Amneal Pharmaceuticals, down from $78.0 million in the prior quarter.
• The five-year high for Profit After Tax was $78.0 million in Q1 2026, with the low at -$242.1 million in Q2 2022.
• Average Profit After Tax over 5 years is -$8.7 million, with a median of $14.3 million recorded in 2024.
• The largest YoY upside for Profit After Tax was 428.82% in 2023 against a maximum downside of 3512.44% in 2023.
• Over 5 years, Profit After Tax stood at $3.8 million in 2022, then plunged by 3512.44% to -$128.6 million in 2023, then surged by 75.83% to -$31.1 million in 2024, then surged by 259.5% to $49.6 million in 2025, then surged by 40.43% to $69.6 million in 2026.
• The last three Profit After Tax figures came in at $69.6 million (Q2 2026), $78.0 million (Q1 2026), and $49.6 million (Q4 2025), per Business Quant data.